BioCrine
  • Home
  • About Us
    • Company and People
    • Board of Directors
    • Management
    • Partners
  • Research Programs
    • Pipeline overview
    • Diabetes as a disease
    • Biocrine drug discovery strategy
    • Serum factor apoCIII
    • Insulin receptor isoforms
    • Calcium channels
    • Inositol pyrophosphates
  • InSight Technology
    • What is it?
    • How does it work?
    • Where can it be used?
  • News
  • Contact
Home » News » Company news » Biocrine’s CEO featured at IVA’s annual meeting

Biocrine’s CEO featured at IVA’s annual meeting

 

 

 

 

On the 28th of October 2011, Biocrine was featured as one of the prominent life science companies on the 92nd annual meeting of IVA. In an interview for IVA, Biocrine’s CEO Per-Olof Berggren talked about the main focus of the research; understanding of how a healthy insulin producing beta cell works, and why it does not do so in a diabetic patient.

IVA stands for IngenjörsVetenskapsAkademin, or Royal Swedish Academy of Engineering Sciences. Since it was founded in 1910, IVA has grown to host 12 departments. Each of them is based on a branch of engineering sciences, such as Electrical Engineering, Biotechnology, and Information Technologies. More than one thousand Swedish and foreign members have been elected into IVA.

The latest annual meeting took place on the 28th of October 2011. More than 700 participants were addressed by IVA’s President, Professor Björn Nilsson. The special theme of his speech was Life Sciences; The impressive progress happening in this area and how is it going to influence our lives today and tomorrow.

Biocrine’s CEO Per-Olof Berggren was interviewed by IVA as a part of  a short movie shown during President Nilsson’s speech. Professor Berggren has explained how Biocrine and the Rolf Luft Center for Diabetes and Endocrinology, Karolinska Institutet, work toward a solution for diabetes. The proprietary InSight technology was discussed as a method to study molecular processes in a living organism.

To learn more about IVA, please follow the link to IVA’s home page.

February 21, 2012 Catharina Rahm

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Categories

Recent posts

  • Professor Berggren’s research publications
    Professor Berggren’s research publications February 6, 2025
  • Årsstämma 17 juni 2024
    Årsstämma 17 juni 2024 June 2, 2024
  • Researchers use the eye as a window to study liver health
    Researchers use the eye as a window to study liver health February 8, 2024
  • ERC Proof of Concept to Professor Per-Olof Berggren
    ERC Proof of Concept to Professor Per-Olof Berggren February 7, 2024
  • The anterior chamber of the eye as a servant to medical research in translation
    The anterior chamber of the eye as a servant to medical research in translation February 7, 2024
  • Lisa Juntti-Berggren receives the Swedish Society of Medicine’s Jubilee Prize
    Lisa Juntti-Berggren receives the Swedish Society of Medicine’s Jubilee Prize February 7, 2024
  • Eye implant may be used to treat diabetes
    Eye implant may be used to treat diabetes February 7, 2024
  • Årsstämma 16 juni 2023
    Årsstämma 16 juni 2023 May 29, 2023
  • New strategy to preserve insulin-producing cells in diabetes
    New strategy to preserve insulin-producing cells in diabetes August 19, 2022
  • Kallelse till årsstämma 27 juni 2022
    Kallelse till årsstämma 27 juni 2022 June 6, 2022

Biocrine AB

Box 3073

169 03 Solna, Sweden

Contact Us

info at biocrine.se

www.biocrine.com

Copyright © 2012 Biocrine AB. All Rights Reserved